IMPEDIMED LIMITED — Call Transcript 2019

May 7, 2019

==> picture [230 x 54] intentionally omitted <==

8 May 2019

ASX ANNOUNCEMENT

Investor conference call – PREVENT interim analysis Q&A with CMO Dr Frank Vicini

Brisbane, Australia and Carlsbad, Calif. – ImpediMed Limited (ASX.IPD), advises it will host an investor Q&A conference call with the Company’s Managing Director and CEO Richard Carreon and Chief Medical Officer Dr Frank Vicini, on Thursday 9 May 2019 at 10:00am AEST.

Dr Vicini will answer questions relating to the manuscript of the PREVENT interim analysis, published in the Annals of Surgical Oncology and announced to the ASX on Monday 6 May 2019.

To pre-register, please follow this link:

https://services.choruscall.com.au/diamondpass/impedimed-10000329-invite.html

You will receive a calendar notification with dial-in details and a PIN for fast track access to the call.

Alternatively, you may also dial in using the following details:

Conference ID: 10000329

Australia Toll Free: 1 800 558 698 New Zealand Toll Free: 0800 453 055 Hong Kong: 800 966 806 Singapore: 800 101 2785 United Kingdom: 0800 051 8245 United States: (855) 881 1339

ENDS.

Richard Carreon Managing Director & CEO

Media Contact:

Kyahn Williamson, WE Buchan T: +61 3 9866 4722 E: kwilliamson@buchanwe.com.au

About ImpediMed

Founded and headquartered in Brisbane, Australia with US and European operations, ImpediMed is the world leader in the design and manufacture of medical devices employing bioimpedance spectroscopy (BIS) technologies for use in the non-invasive clinical assessment and monitoring of tissue composition and fluid status.

ImpediMed produces a family of FDA cleared and CE Marked medical devices, including SOZO[®] for multiple indications including heart failure and lymphoedema, sold in select markets globally.

For more information, visit www.impedimed.com.